Pre-Open Stock Movers 01/22: (AKCA) (ACMR) (SPCE) Higher; (FCEL) (NVAX) (BPMC) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Applied Therapeutics Inc. (APLT) Prices 2.74M Share Upsized Common Offering at $45.50/Sh
January 24, 2020 5:43 AM ESTApplied Therapeutics, Inc. (NASDAQ: APLT) today announced the pricing of its public offering of 2,741,489 shares of its common stock, par value $0.0001 per share, at a price to the public of $45.50 per share. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering... More
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q
January 23, 2020 6:39 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 4Q earnings report. Chen continues to believe that upward earnings revisions to JNJ's Pharma business and multiple expansion, driven by diminishing headlines... More
Blueprint Medicines (BPMC) Prices 4.71M Share Common Offering at $69/Sh
January 23, 2020 5:53 AM ESTBlueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the pricing of an underwritten public offering of 4,710,144 shares of its common stock at a public offering price of $69.00 per share, before underwriting... More
UPDATE: UBS Resumes Tesla (TSLA) at Sell
January 23, 2020 4:35 AM EST(Updated - January 23, 2020 6:50 AM EST)
(updating comment)
UBS analyst Colin Langan raised the price target on Tesla (NASDAQ: TSLA) to $410.00 (from $160.00) while maintaining a Sell rating as he resumes coverage of the auto maker.
The analyst comments "We take... More
